Innovations and Inaugurations: Bill Clinton

Innovations and Inaugurations: Bill Clinton

01.16.13 | By Mark Grayson

When President Clinton was first inaugurated in 1993, HIV/AIDS was continuing its inexorable devastation in the U.S. with 14 deaths per 100,000 patients. This would climb to 16 deaths per 100,000 in 1995. By the time President Clinton started his second term in 1997, the rate had dropped dramatically to only 6 deaths per 100,000 patients.

How did this happen so quickly? Through the tenacity of the researchers at biopharmaceutical companies, academia and federal research institutions, new therapies were discovered and approved by the Food and Drug Administration that finally were able to slow the progression of the disease. The progress has been realized through a complex process of incremental gains that have unfolded over many years-and today the death rate is only 2 in 100,000 patients. Doctors and scientist also found the combination therapy or highly active antiretroviral therapy (HAART) made the new medicines even more potent.

We have come a long way since President Clinton's second inauguration. But we know that much more needs to be done for people not only in the U.S. but also all around the world. Let's hope that U.S. continues to value the innovation that enables biopharmaceutical companies to find more treatments for HIV and other deadly diseases.

More On PhRMA — powered by PhRMApedia


Cost in Context